BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers

BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Y-K, Choi, E, Kim, M A, Park, P-G, Park, N-H, Lee, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720250/
https://www.ncbi.nlm.nih.gov/pubmed/19603021
http://dx.doi.org/10.1038/sj.bjc.6605161
_version_ 1782170126822408192
author Lee, Y-K
Choi, E
Kim, M A
Park, P-G
Park, N-H
Lee, H
author_facet Lee, Y-K
Choi, E
Kim, M A
Park, P-G
Park, N-H
Lee, H
author_sort Lee, Y-K
collection PubMed
description BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A. METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been tracked after first-line treatment. RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months, respectively (P<0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade. In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed. CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
format Text
id pubmed-2720250
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27202502010-08-04 BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers Lee, Y-K Choi, E Kim, M A Park, P-G Park, N-H Lee, H Br J Cancer Molecular Diagnostics BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A. METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been tracked after first-line treatment. RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months, respectively (P<0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade. In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed. CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Nature Publishing Group 2009-08-04 2009-07-14 /pmc/articles/PMC2720250/ /pubmed/19603021 http://dx.doi.org/10.1038/sj.bjc.6605161 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Lee, Y-K
Choi, E
Kim, M A
Park, P-G
Park, N-H
Lee, H
BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title_full BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title_fullStr BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title_full_unstemmed BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title_short BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
title_sort bubr1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720250/
https://www.ncbi.nlm.nih.gov/pubmed/19603021
http://dx.doi.org/10.1038/sj.bjc.6605161
work_keys_str_mv AT leeyk bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers
AT choie bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers
AT kimma bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers
AT parkpg bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers
AT parknh bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers
AT leeh bubr1asaprognosticmarkerforrecurrencefreesurvivalratesinepithelialovariancancers

Ejemplares similares